Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis

Chaitanya, B.; Pai, Keerthilatha M.; Yathiraj, Prahlad H; Fernandes, Donald J; Chhaparwal, Yogesh

doi:10.1016/j.oraloncology.2017.07.024

Cited by 23 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, extensive research has been conducted to determine the effectiveness of a vast number of diverse interventions for the prevention or treatment of OM in cancer patients. Several agents and methods such as cryotherapy, growth factors, anti‐inflammatory agents, antioxidants and low‐level laser therapy (LLLT) have been tested to reduce the severity of, or prevent mucositis; however, none of them has been conclusively validated to be considered as a standard treatment …”

Section: Introductionmentioning

confidence: 99%

“…Several agents and methods such as cryotherapy, growth factors, anti-inflammatory agents, antioxidants and low-level laser therapy (LLLT) have been tested to reduce the severity of, or prevent mucositis; however, none of them has been conclusively validated to be considered as a standard treatment. [8][9][10][11][12] To date, palifermin, a keratinocyte growth factor, is the only drug for the prevention of OM that has been approved by the US Food and Drug Administration (FDA) in 2004. It was approved in the treatment of OM in patients with hematologic malignancies who receive high doses of chemotherapy and radiation therapy followed by stem cell rescue.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Oral administration of nanomicelle curcumin in the prevention of radiotherapy‐induced mucositis in head and neck cancers

Delavarian

Pakfetrat

Ghazi

et al. 2019

Special Care in Dentistry

View full text Add to dashboard Cite

Oral mucositis (OM) is a complication of head and neck cancer (HNC) therapy with negative impact on the quality of life. Although definitive treatment has not yet been established, there is interest towards the use of natural compounds owing to their few side effects. Curcumin has a variety of biological and pharmacological properties including anticancer and anti‐inflammatory effects. Aim The aim of this study is to evaluate the effect of curcumin in the form of nanomicelle on OM in HNC patients receiving radiotherapy. Methods In this clinical trial, 32 HNC patients were allocated to case and control groups, and respectively received nanocurcumin or placebo during radiotherapy. Results We found a statistically significant difference in the severity of mucositis between the 2 groups at all visits. In contrast to the control‐group patients, who all developed OM in the 2nd week of radiotherapy, only 32% of the case group developed OM with no obvious oral or systemic side effects. Conclusion Our data show that nanomicelle curcumin is an effective agent in the prevention of OM or reducing its severity. Thus, the administration of nanocurcumin can be considered as a reasonable approach to hinder the development of OM in HNC patients requiring radiotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Oral administration of nanomicelle curcumin in the prevention of radiotherapy‐induced mucositis in head and neck cancers

Delavarian

Pakfetrat

Ghazi

et al. 2019

Special Care in Dentistry

View full text Add to dashboard Cite

show abstract

“…The efficacy of REB for the treatment of oral mucositis was first reported by Matsuda et al in 1994, and a resulting mouthwash containing REB has been used as a therapy for mucositis caused by radiotherapy [ 15 ], chemotherapy [ 16 ] and Behcet’s disease [ 7 ]. Furthermore, a pilot randomized controlled trial (RCT) reported that mouthwash containing REB reduces the onset of oral mucositis caused by chemoradiotherapy and radiotherapy [ 15 , 17 , 18 ]. The various pharmacological effects of REB include suppression of the induction of mucus secretion [ 19 ], promotion of endogenous prostaglandin production in the gastric mucosa [ 20 , 21 ], anti-free radical action [ 12 ], neutrophil activation [ 22 , 23 ], inhibition of inflammatory reactions [ 24 , 25 , 26 ] and up-regulation of epidermal growth factor and its receptor [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

Hydrogel Formulations Incorporating Drug Nanocrystals Enhance the Therapeutic Effect of Rebamipide in a Hamster Model for Oral Mucositis

et al. 2020

View full text Add to dashboard Cite

A mouthwash formulation of rebamipide (REB) is commonly used to treat oral mucositis; however, this formulation does not provide sufficient treatment or prevention in cases of serious oral mucositis. To improve treatment, we attempted to design a hydrogel incorporating REB nanocrystals (R-NPs gel). The R-NPs gel was prepared by a bead mill method using carbopol hydrogel, methylcellulose and 2-hydroxypropyl-β-cyclodextrin, and another hydrogel incorporating REB microcrystals (R-MPs gel) was prepared following the same protocol but without the bead mill treatment. The REB particle size in the R-MPs gel was 0.15–25 μm, and while the REB particle size was 50–180 nm in the R-NPs gel. Next, we investigated the therapeutic effect of REB nanocrystals on oral mucositis using a hamster model. Almost all of the REB was released as drug nanocrystals from the R-NPs gel, and the REB content in the cheek pouch of hamsters treated with R-NPs gel was significantly higher than that of hamsters treated with R-MPs gel. Further, treatment with REB hydrogels enhanced the healing of oral wounds in the hamsters. REB accumulation in the cheek pouch of hamsters treated with the R-NPs gel was prevented by an inhibitor of clathrin-dependent endocytosis (CME) (40 μM dynasore). In conclusion, we designed an R-NPs gel and found that REB nanocrystals are taken up by tissues through CME, where they provide a persistent effect resulting in an enhancement of oral wound healing.

show abstract

“…Oral cryotherapy prevented stomatitis in patients receiving bolus doses of 5-fluorouracil and haematopoietic stem cell transplantation 5. Rebamipide is an internal-use mucosal protectant, and gargling with rebamipide has been reported to prevent stomatitis in patients with head and neck cancer who are receiving chemoradiotherapy 6 7. However, recommendations for preventing chemotherapy-induced stomatitis in patients with breast cancer are lacking.…”

Section: Introductionmentioning

confidence: 99%

Study protocol for efficacy and safety of steroid-containing mouthwash to prevent chemotherapy-induced stomatitis in women with breast cancer: a multicentre, open-label, randomised phase 2 study

et al. 2020

View full text Add to dashboard Cite

IntroductionStomatitis is a frequent adverse event in patients undergoing chemotherapy for breast cancer. Stomatitis can hamper oral nutrition resulting in malnutrition, reduce quality of life and introduce the need for dose reductions and interruption of chemotherapy; however, there is currently no standard approach for preventing chemotherapy-induced stomatitis. We aimed to assess the safety and efficacy of a dexamethasone-based elixir mouthwash for preventing chemotherapy-induced stomatitis in patients with early breast cancer.Methods and analysisIn this multicenter, randomised, controlled phase 2 trial, we will randomly assign 120 women with early breast cancer undergoing chemotherapy to use of a dexamethasone-based elixir or standard oral care, to compare their preventive effects on chemotherapy-induced stomatitis. Patients will be assigned in a 1:1 ratio. Patients in the intervention group will receive chemotherapy, oral care and a dexamethasone-based elixir (10 mL 0.1 mg/mL; swish for 2 min and spit, four times daily for 9 weeks), and patients in the control group will receive chemotherapy and oral care. The primary endpoint is the difference in incidence of stomatitis between the two groups. The sample size allows for the detection of a minimum difference of 20% in the incidence of stomatitis between the two groups. Secondary endpoints are severity of stomatitis, duration of stomatitis, completion rate of chemotherapy and adverse events.Ethics and disseminationAll participants signed a written consent form, and the study protocol has been reviewed and approved by the Clinical Research Review Board of Nagasaki University (CRB7180001).Trial registration numberUMIN Clinical Trials Registry (UMIN000030489).

show abstract

Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis

Cited by 23 publications

References 8 publications

Oral administration of nanomicelle curcumin in the prevention of radiotherapy‐induced mucositis in head and neck cancers

Oral administration of nanomicelle curcumin in the prevention of radiotherapy‐induced mucositis in head and neck cancers

Hydrogel Formulations Incorporating Drug Nanocrystals Enhance the Therapeutic Effect of Rebamipide in a Hamster Model for Oral Mucositis

Study protocol for efficacy and safety of steroid-containing mouthwash to prevent chemotherapy-induced stomatitis in women with breast cancer: a multicentre, open-label, randomised phase 2 study

Contact Info

Product

Resources

About